PLAT and Hyperglycemia: In addition, hyperglycemia attenuates the therapeutic effect of early tissue plasminogen activator (IV-tPA) in patients with IS and contributes to the alteration of blood-brain screen permeability in the context of tPA (42, 43), both of which cause cognitive dysfunction.